Univariate analysis of factors potentially associated with grade III-IV aGVHD in 106 DCBT recipients
| Variable . | N . | Day 180 grade III-IV aGVHD, % (95% CI) . | P . |
|---|---|---|---|
| Age, y | |||
| 0-15 | 14 | 21 (5-46) | .921 |
| ≥16 | 92 | 21 (13-30) | |
| Conditioning | |||
| Myeloablative | 80 | 20 (12-29) | .764 |
| Nonmyeloablative | 26 | 23 (9-41) | |
| Infused total CD3+cell dose | |||
| ≤7.74 × 106/kg | 55 | 26 (15-38) | .170 |
| >7.74 × 106/kg | 51 | 16 (7-27) | |
| Dominant unit-recipient 6 allele HLA match | |||
| Worse HLA match: 2-3/6 | 28 | 32 (16-50) | .077 |
| Better HLA match: 4-6/6 | 78 | 17 (9-26) | |
| ST2 level, ng/mL | |||
| Low: ≤33.9 | 56 | 13 (5-23) | .024 |
| High: >33.9 | 50 | 30% (18-43) |
| Variable . | N . | Day 180 grade III-IV aGVHD, % (95% CI) . | P . |
|---|---|---|---|
| Age, y | |||
| 0-15 | 14 | 21 (5-46) | .921 |
| ≥16 | 92 | 21 (13-30) | |
| Conditioning | |||
| Myeloablative | 80 | 20 (12-29) | .764 |
| Nonmyeloablative | 26 | 23 (9-41) | |
| Infused total CD3+cell dose | |||
| ≤7.74 × 106/kg | 55 | 26 (15-38) | .170 |
| >7.74 × 106/kg | 51 | 16 (7-27) | |
| Dominant unit-recipient 6 allele HLA match | |||
| Worse HLA match: 2-3/6 | 28 | 32 (16-50) | .077 |
| Better HLA match: 4-6/6 | 78 | 17 (9-26) | |
| ST2 level, ng/mL | |||
| Low: ≤33.9 | 56 | 13 (5-23) | .024 |
| High: >33.9 | 50 | 30% (18-43) |